Mumbai: Jubilant Biosys, the Bangalore-based subsidiary of drug and food company Jubilant Life Sciences Ltd, said on Thursday it had expanded its drug discovery alliance with Belgian drug researcher Janssen Pharmaceutica NV to multiple therapeutic areas.

The Jubilant-Janssen collaboration, signed in 2011, was aimed at delivering pre-clinical drug candidates to Janssen. The new agreement for multiple therapeutic areas is owing to Jubilant’s diversified expertise in various therapeutic areas.

Most of the research will be undertaken at Jubilant Biosys in India and some at Jubilant Discovery Center in the US.

Janssen is a group company of US drug maker Johnson and Johnson.

Jubilant will carry out research services and deliver all pre-clinical candidates to Janssen for potential development and commercialization.

In addition to research funding, Jubilant will receive milestone-based payments and royalty should Janssen successfully progress the assets into clinical development and commercialization. Other financial details of the collaboration were not disclosed.

“We are pleased to announce the expansion of the Janssen-Jubilant collaboration and look forward to discovering novel chemical entities that address the unmet medical needs in important disease areas," said Subir K. Basak, president, Jubilant Biosys, global drug discovery services.

The promoters of HT Media Ltd, which publishes Hindustan Times and Mint, and Jubilant Life Sciences are closely related. There are no promoter crossholdings.

Close